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 CETP is not causally related to subclinical atherosclerosis in the total population 2 
 CETP is related to atherosclerosis in normoglycemic men and (pre)diabetic women 3 




Several trials to prevent cardiovascular disease by inhibiting cholesteryl ester transfer protein 2 
(CETP) have failed, except REVEAL. Thus far, it is unclear to what extent CETP is causally related 3 
to measures of atherosclerosis. 4 
Objective 5 
To study the causal relation between genetically-determined CETP concentration and carotid 6 
intima media thickness (cIMT) in a population-based cohort study.  7 
Methods 8 
In the Netherlands Epidemiology of Obesity study, participants were genotyped, and cIMT was 9 
measured by ultrasonography. We examined the relation between a weighted genetic risk score for 10 
CETP concentration, based on 3 SNPs that have previously been shown to largely determine CETP 11 
concentration and cIMT using Mendelian randomisation in the total population and in strata by sex, 12 
Framingham 10-year risk, (pre)diabetes, HDL-cholesterol, triglycerides and statin use.  13 
Results 14 
We analysed 5,655 participants (56% women) with a mean age of 56 (range 44-66) years, BMI of 15 
26 (range 17-61) kg/m
2
 and serum CETP of 2.47 (range 0.68-5.33) µg/mL. There was no evidence for 16 
a causal relation between genetically-determined CETP and cIMT in the total population, but 17 
associations were differently directed in men (16µm per µg/mL increase in genetically-determined 18 
CETP; 95% CI: -8, 39) and women (-8 µm; -25, 9). Genetically-determined CETP appeared to be 19 
associated with cIMT in normoglycemic men (26 µm; -1, 52) and in (pre)diabetic women (48 µm; -2, 20 
98).  21 
Conclusion 22 
In this population-based study, there was no causal relation between genetically-determined CETP 23 
concentration and cIMT in the total population, although we observed directionally differing effects in 24 
4 
 
men and women. Stratified results suggested associations in individuals with different 1 
cardiometabolic risk factor profiles, which require replication. 2 
Keywords: Reverse cholesterol transport, Atherosclerosis, Mendelian randomisation, Cohort, 3 
Epidemiology  4 




Recent studies to improve cardiovascular risk prevention have focussed on cholesteryl ester 2 
transfer protein (CETP) inhibitors since they increase HDL-c and decrease non-HDL-c 3 
concentrations. 
1-3
   4 
CETP facilitates the migration of cholesteryl esters from HDL to LDL and very low-density-5 
lipoproteins (VLDL). A high CETP concentration  is therefore hypothesized to contribute to an 6 
atherogenic lipoprotein profile by increasing (V)LDL-c and decreasing HDL-c.
4
 Several observational 7 
studies have suggested that lower concentrations of CETP are associated with reduced CVD risk. 
5,6
 8 
Most recent efforts to lower CETP concentration pharmacologically with the purpose of reducing 9 
CVD risk have been unsuccessful, except for the REVEAL trial, in which CETP inhibition with 10 
anacetrapib successfully lowered the risk of major coronary events in high-cardiovascular risk 11 
patients. 
7,8
 The effect of genetically determined CETP has been subject to considerable discussion in 12 
recent literature, but in general a detrimental effect of high CETP, if any, appears to be restricted to 13 
men 
2,4,8-18
 Close inspection of previous studies on the association of CETP with CVD risk suggested 14 
that in addition to sex, other  factors potentially modulate the effects of CETP on CVD risk, including 15 
HDL-c or triglyceride concentrations, insulin resistance, or the use of statins or fibrates. 
1,9,19-21
 This 16 
suggests that CETP inhibition could be effective in specific subgroups of the population. To provide 17 
more insights in the role of CETP on cardiovascular risk , we aimed to study the causal effect of 18 
genetically determined higher CETP concentration on atherosclerosis in the general low-risk 19 
population, as well as specific subgroups, using a genetic risk score for CETP concentration as 20 




Study design and study population 2 
The Netherlands Epidemiology of Obesity (NEO) study is a population-based, prospective cohort 3 
study of 6,671 men and women aged between 45 and 65 years. The study design and population are 4 
described in detail elsewhere.
22
 All inhabitants with a self-reported body mass index (BMI) of 27 5 
kg/m
2
 or higher and living in the greater area of Leiden, the Netherlands were eligible to participate in 6 
the NEO study. In addition, all inhabitants aged between 45 and 65 years from one adjacent 7 
municipality (Leiderdorp, the Netherlands) were invited to participate irrespective of their BMI, 8 
allowing for a reference distribution of BMI. Participants visited the NEO study centre for extensive 9 
baseline measurements, including blood sampling and cIMT. Research nurses recorded current 10 
medication use by means of a medication inventory. Prior to the study visit, participants completed 11 
questionnaires at home with respect to demographic, lifestyle, and clinical information.  12 
 The Medical Ethical Committee of the Leiden University Medical Centre (LUMC) approved the 13 
protocol. All participants gave their written informed consent. 14 
For the present analyses, we excluded participants from non-European ancestry or with poor 15 
genotyping quality (n=927) : when the sample call rate was <98%, there was a sex mismatch, 16 
heterozygosity rate was not within ±3 SD of mean heterozygosity rate, participants differed based on 17 
the first two principal components (PCs) (±3.5 SD), samples were duplicates, or concordance with 18 
another DNA sample was >0.25 (related individuals). Furthermore, we excluded participants with 19 
missing CETP (n=31) and cIMT measurement (n=58). 20 
Blood sampling 21 
During the visit to the NEO study centre, venous blood samples were obtained from the 22 
antecubital vein after a >10 hour overnight fast. Fasting serum total cholesterol and TG concentrations 23 
were measured with enzymatic colorimetric assays (Roche Modular P800 Analyzer, Roche 24 
Diagnostics, Mannheim, Germany) and fasting serum HDL-c concentrations with third generation 25 
7 
 
homogenous HDL-c methods (Roche Modular P800 Analyzer, Roche Diagnostics, Mannheim, 1 
Germany). LDL-c concentrations were calculated using the Friedewald equation.
23
 Furthermore, 2 
aliquots of plasma and serum were stored at -80°C after centrifugation. DNA was extracted and 3 
genotyping was performed by the Centre National de Génotypage (Evry Cedex, France), using the 4 
Illumina HumanCoreExome-24 BeadChip (Illumina Inc., San Diego, California, United States of 5 
America). Subsequently, genotypes were imputed to the 1000 Genome Project reference panel (v3 6 
2011) using IMPUTE (v2.2) software. 
24,25
 Three variants within the CETP gene were discovered in a 7 
genome wide association study in this population: rs12720922, rs247616 and rs1968905 were used 8 
for the present study, of which rs12720922 and rs1968905 were imputed variants (Blauw et al, 9 
submitted).  10 
CETP concentrations were measured in serum that had undergone one previous freeze-thaw cycle 11 
with enzyme-linked immune sorbent assay (ELISA) kits according to the manufacturer’s instructions 12 
(DAIICHI CETP ELISA, Daiichi, Tokyo, Japan; coefficient of variation 11.7%).  13 
Subclinical atherosclerosis 14 
Carotid intima media thickness (cIMT) was used as a measure of subclinical atherosclerosis. 15 
cIMT was assessed by ultrasonography of the common carotid arteries (CCA). A 15 mm long section 16 
10 mm proximal of the CCA bifurcation was measured while the subject was in supine position. cIMT 17 
was measured using a 7.5–10 MHz linear-array probe and the Art.Lab system in B-mode setting and 18 
using a wall-track system (ART.LAB version 2.1, Esaote, Maastricht, The Netherlands) to detect 19 
boundaries between lumen and intima, as well as between media and adventitia. cIMT was measured 20 
during six heart beats in angles of 180, 135 and 90 degrees (right CCA) and 180, 225 and 270 degrees 21 
(left CCA). We calculated the mean IMT for each participant by averaging the 36 cIMT 22 
measurements within each individual. Measurements of cIMT were validated by analysing repeated 23 
measurements in 169 randomly selected participants, which resulted in an intra-observer CV of 5.8% 24 




Other variables 1 
On the questionnaire, participants reported their highest level of education in ten categories 2 
according to the Dutch education system, which was further reclassified into low (none, primary 3 
school or lower vocational education) or high (other). Participants reported their medical history of 4 
diabetes and cardiovascular diseases. Pre-existing CVD was defined as myocardial infarction, angina 5 
pectoris, congestive heart failure, stroke, or peripheral vascular disease. In addition, all use of 6 
medication in the month preceding the study visit was recorded. Tobacco smoking was reported in 7 
three categories: never smoker, former smoker or current smoker. Participants reported their physical 8 
activity during leisure time, which was expressed in metabolic equivalent hours per week. 9 
Menopausal state was categorized in pre-, and postmenopausal state according to information on 10 
ovariectomy, hysterectomy and self-reported state of menopause in the questionnaire. The 11 
Framingham 10-year risk of cardiovascular disease was calculated by summation of component 12 
scores based on age, LDL-c, HDL-c, diastolic and systolic blood pressure, diabetes, and smoking. 
26
  13 
Statistical analysis 14 
The present study is a cross-sectional analysis of the baseline measurements of the NEO study. In 15 
the NEO study, individuals with a BMI of 27 kg/m
2
 or higher were oversampled. To represent 16 
baseline associations in the general population  adjustments for the oversampling of individuals with a 17 




 This was done by weighting all participants towards the BMI 18 
distribution of participants from the Leiderdorp municipality.
28
 The BMI distribution of the 19 
participants from Leiderdorp was similar to the BMI distribution of the general Dutch population.
29
 20 
All results were based on weighted analyses.  21 





percentiles; non-normally distributed data only), or as percentage (categorical data).  23 
We examined the observational association between CETP concentration and cIMT using 24 
multivariate linear regression analysis. Results are presented as beta coefficients with 95% confidence 25 
intervals (CI) which can be interpreted as difference in cIMT (µm) per unit (µg/mL) of measured 26 
9 
 
CETP concentration. These regression models were adjusted for age and sex, LDL-c concentrations, 1 
ethnicity, education, physical activity and smoking. Adjustment for LDL-c was performed to evaluate 2 
the association between CETP and IMT through HDL-c. Because it is not completely known whether 3 
the following factors are common causes of both CETP and cIMT, and therefore their role as 4 
confounding factors is doubted, we performed separate observational analyses additionally adjusted 5 
for statin use, diabetes and hypertension. 6 
We calculated a weighted genetic risk score (GRS) by summation of the products of the number 7 
of alleles per SNP and the effect size per allele. We estimated the association of the separate SNPs 8 
and the GRS with CETP concentrations using linear regression analyses. 9 
We estimated the causal relation between the separate SNPs for CETP concentration and cIMT 10 
using linear regression analyses, and we examined the causal association between CETP 11 
concentration and cIMT using an instrumental variable two-stage-least-squares regression analysis in 12 
which CETP concentration was instrumented by a genetic risk score composed by the three genetic 13 
variants in the CETP gene. The regression coefficients from these analyses can be interpreted as 14 
difference in cIMT (µm) per unit (µg/mL) in genetically-determined CETP concentration. 15 
The analyses were performed in the total population, and separately for pre-specified subgroups 16 
based on sex, high CVD risk profile (defined as a Framingham predicted 10-year risk of 10% or 17 
higher), (pre)diabetes (defined as having fasting glucose concentrations ≥6.1 mmol/L, self-reported 18 
diabetes or using glucose-lowering medication), high HDL-c concentration (with a cut-off value of 19 
1.04 mmol/L in men, and 1.30 mmol/L in women), triglyceride concentration (with a cut-off value of 20 
1.7 mmol/L), statin use, and menopausal status. 
30-32
 21 
Analyses were performed in Stata (version 14, StataCorp. 2015) 22 




Baseline characteristics 2 
Table 1 – Baseline characteristics of the participants of the Netherlands Epidemiology of Obesity study, men and 3 




CETP ≤ median 
(2.60 µg/mL) 
CETP > median 
(2.60 µg/mL) 
Age (y) 56 (6) 56 (6) 56 (6) 
Sex (male) 44 52 36 
BMI (kg/m2) 26 (4) 26 (4) 26 (4) 
Tobacco smoking (% never) 38 36 41 
Physical activity (MET h/week) 30 (16-50) 30 (16-50) 30 (16-50) 
Education level (% high) 47 49 46 
    
(Pre)diabetes (%) 14 17 11 
Hypertension (%) 34 34 34 
CVD (%) 5 7 3 
Statin use (%) 10 15 5 
Framingham 10-year risk ≥10% 24 24 23 
    
Total cholesterol (mmol/L) 5.7 (1.0) 5.5 (1.0) 5.9 (1.0) 
HDL cholesterol (mmol/L) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 
LDL cholesterol (mmol/L) 3.5 (1.0) 3.3 (0.9) 3.8 (0.9) 
Triglycerides (mmol/L) 1.2 (0.9) 1.2 (0.8) 1.2 (0.9) 
CETP (µg/mL) 2.47 (0.65) 1.96 (0.32) 2.98 (0.47) 
    
Coding allele rs247616 (%) 56 66 46 
Coding allele rs12720922 (%) 17 11 23 
Coding allele rs1968905 (%) 82 80 84 
Results were based on analyses weighted towards the BMI distribution of the general population (2,715 men and 5 
2,940 women) 6 




 percentiles) or percentage 7 
BMI, body mass index; CETP, cholesteryl ester transfer protein; cIMT, carotid intima media thickness; HDL, 8 
high density lipoprotein; LDL, low density lipoprotein; MET, metabolic equivalent of task; NEO, Netherlands 9 
Epidemiology of Obesity 10 
  11 
11 
 
Baseline characteristics of the study population are presented in Table 1, stratified by sex. The 1 
mean (SD) age of the participants was 56 (6) years, and 56% were women. The mean BMI was 26 (4) 2 
kg/m
2
, mean CETP concentration was 2.47 (0.65) µg/mL, and the mean cIMT was 616 (92) µm.  3 
Serum CETP concentration and atherosclerosis 4 
Table 2 – Associations of observed CETP concentrations (adjusted), CETP SNPs, and genetically-determined CETP 5 
concentrations with the intima media thickness in the total population of the Netherlands Epidemiology of Obesity study (n 6 
= 5,655) and in men and women separately. 7 
 Difference in cIMT in µm (95% CI) 
  cIMT Total population Men (44%) Women (56%) 
CETP concentration (per 
µg/mL) (crude) 
-2 (-7, 4) 8 (-1, 17) -0 (-7, 6) 
CETP concentration (per 
µg/mL) (adjusted) 
-1 (-6, 5) 10 (1, 19) -7 (-14, -1) 
CETP concentration (per 
µg/mL) (additionally adjusted) 
-1 (-6, 5) 10 (1, 19) -7 (-14, -0) 
rs1968905-G (per risk-
increasing allele) 
2 (-5, 9) -2 (-13, 10) 3 (-7, 12) 
rs247616-C (per risk-increasing 
allele) 
0 (-5, 6) -4 (-12, 4) 4 (-4, 11) 
rs12720922-A (per risk-
increasing allele) 
2 (-5, 8) 7 (-3, 17) -3 (-11, 5) 
Genetically-determined  CETP 
(µg/mL) 
2 (-12, 16) 16 (-8, 39) -8 (-25, 9) 
Results were based on analyses weighted towards the BMI distribution of the general population (n=5,655), and 8 
were derived from beta coefficients (95% CI) from linear regression and expressed as difference in cIMT µm. 9 
Results for the genetic risk score were presented as µm difference in cIMT per µg/mL genetically-determined 10 
CETP concentration. Observational analyses were adjusted for age, LDL-c concentration, ethnicity, education, 11 
physical activity, and smoking. The additionally adjusted model was additionally adjusted for statin use, 12 
diabetes and hypertension. The observational analyses in the total population was additionally adjusted for sex. 13 
 14 
CETP, cholesteryl ester transfer protein; cIMT, intima media thickness; LDL-c, low density lipoprotein 15 
cholesterol; SNP, single nucleotide polymorphism 16 
 17 
In observational analyses in the total population, CETP concentration was weakly associated with  18 
cIMT (adjusted coefficient: -1 µm per µg/mL CETP; 95% CI: -6, 5). Table 2 reports stratified 19 
analyses with a weak positive association in men (10 µm per µg/mL higher CETP concentration; 95% 20 
CI: 1, 19) and a weak negative association in women (-7 µm per µg/mL CETP; 95% CI: -14, -0)  21 
Associations between genetically-determined CETP and atherosclerosis 22 
12 
 
The genetic risk score (GRS) of three independent CETP SNP risk alleles rs247616-C, 1 
rs12720922-A, and rs1968905-G accounted for 14.7% of variation in CETP concentrations in the 2 
participants of the NEO study. 3 
 4 
 5 
Figure 1 – Associations with 95% confidence intervals of SNPs rs1968905, rs247616, and rs12720922 and the 6 
genetic risk score composed from these SNPs with serum CETP concentrations in the participants of the Netherlands 7 
Epidemiology of Obesity study, men and women aged between 45 and 65 year (n=5,655). Associations are expressed 8 
in µg/mL CETP per allele of the SNPs or per unit of the genetic risk score. 9 
Figure 1 reports the difference in CETP concentration per CETP-increasing SNP allele and per 10 
point increase in GRS: 0.78 µg/mL (95% CI: 0.73, 0.83). Table 2 reports causal relations between 11 
variations in the CETP gene and cIMT. CETP was not causally related to cIMT in the total study 12 
population. We observed a causal relation between CETP and cIMT in men of 16 µm (95% CI: -8, 13 
39) difference in cIMT per µg/mL genetically-determined CETP in men and -8 µm (95% CI: -25, 9) 14 
in women. 15 
Subgroup analyses 16 
Men and women were stratified for CVD risk profile, (pre)diabetes, fasting HDL-c, triglycerides 17 
and statin use. The results of the stratified analyses reported in Figure 2 and Figure 3 demonstrate that 18 
13 
 
in men with a low 10-year Framingham risk, one µg/mL genetically-determined CETP was related to 1 
12 µm (95% CI: -12, 36) thicker cIMT, while in men with a 10-year risk ≥10% the relation was 24 2 
µm (95% CI: -25, 72) per µg/mL genetically-determined CETP. In men without (pre)diabetes one 3 
µg/mL genetically-determined CETP was related with 26 µm (95% CI: -1, 52) thicker cIMT per 4 
µg/mL, and with -24 µm (95% CI: -66, 18) in men with (pre)diabetes. In men with normal HDL-c, 5 
normal TG concentrations, or not using statins, the associations ranged between 19 and 21 µm per 6 
µg/mL genetically-determined CETP concentration, while in men with low HDL-c CETP was 7 
inversely related to cIMT (-20 µm per µg/mL CETP; 95% CI: -67, 27).  8 
One µg/mL genetically-determined CETP was related with a -17 µm (95% CI: -36, 1) difference 9 
in cIMT in women with a low 10-year Framingham risk, while in women with a 10-year Framingham 10 
risk ≥10% this relation was 23 µm (95% CI: -14, 59) per µg/mL genetically-determined CETP. In 11 
women with (pre)diabetes, one µg/ml genetically-determined CETP was related with a 48 µm (95% 12 
CI: -2, 98) thicker cIMT, and with -13 µm (95% CI: -31, 5) difference in cIMT in women without 13 
(pre)diabetes. We observed relations close to the null in women with low HDL-c, high TG 14 
concentrations, or who used statins. In women with normal HDL-c, fasting TG, or not using statins, 15 
the relations ranged between -9 and -14 µm per µg/mL CETP. In premenopausal women, one µg/mL 16 
genetically-determined CETP was related with a -25 µm (95% CI: -59, 8) difference in cIMT, and -0 17 





Figure 2 – Associations between (genetically determined) serum CETP concentrations (µg/mL) and intima media 3 
thickness (µm) in men participating in the Netherlands Epidemiology of Obesity study, aged 45-65 years (n=2,715). 4 
CETP, cholesteryl ester transfer protein; cIMT, carotid intima media thickness; CVD, cardiovascular disease; HDL-5 
c, high density lipoprotein cholesterol; TG, triglycerides. 6 





Figure 3 – Associations between (genetically determined) serum CETP concentrations (µg/mL) and intima media 3 
thickness (µm) in women participating in the Netherlands Epidemiology of Obesity study, aged 45-65 years (n=2,940). 4 
CETP, cholesteryl ester transfer protein; cIMT, carotid intima media thickness; CVD, cardiovascular disease; HDL-5 






In 5,655 men and women, we investigated the causal associations between CETP and measures of 2 
subclinical atherosclerosis. We showed that there was a marginal observational association between 3 
CETP and subclinical atherosclerosis in the study population, while a genetic propensity towards 4 
higher CETP concentrations was not associated with cIMT. However, stratified analyses in 5 
prespecified subgroups of sex, cardiovascular risk, (pre)diabetes, HDL-c, triglycerides and statin use 6 
suggested a marginal association between higher CETP and thicker cIMT in men, and a minimal 7 
association in the opposite direction in women, albeit with wide confidence intervals.  8 
The null results in the total study population of this study are consistent with findings in the total 9 
population in previous Mendelian randomisation studies and randomised controlled trials, however 10 
some Mendelian randomisation studies did not measure CETP concentrations. 
8,14-17
 Our findings 11 
indicate that if a relation between CETP concentrations and subclinical measures of CVD is present, 12 
this may be restricted to men, and to women with a moderate-to-high cardiovascular risk or 13 
(pre)diabetes in a middle aged population. Our results in high-cardiovascular risk individuals are 14 
consistent with the results of the REVEAL trial, that showed a small decrease in incidence of major 15 
coronary events in patients with atherosclerotic vascular disease treated with anacetrapib, compared 16 
with placebo. 
7
 These findings are consistent with the positive relations between CETP and subclinical 17 
and clinical CVD that were observed mainly in studies in predominantly men.
1,2,5,9,18
 Our findings in 18 
women with (pre)diabetes are supported by a smaller previous study that reported that higher 19 
observed CETP concentrations were associated with CVD risk in women with type 2 diabetes, but we 20 
observed subgroup effects in men that were not observed by this previous study.
33
  21 
CETP mediates the transfer of cholesteryl ester from HDL towards LDL, which is generally 22 
assumed to be detrimental with respect to the development of CVD.
34,35
  The surprising absence of an 23 
association between CETP and subclinical atherosclerosis on a population level is consistent with the 24 






 clinical trials of 25 
pharmacologic CETP inhibition, due to futility or inferiority. However, the ineffectiveness of drugs 26 
17 
 
that target an increase in HDL-c via CETP in the general population may be explained by opposing 1 
effects in subgroups that may be masked in summary effect estimates. Although most clinical trials 2 
may likely not be powered to perform stratified analyses, reporting stratum-specific effect estimates 3 
may reveal different relations in subgroups.  4 
The observed sex differences may be explained by a difference in the relative contribution of a 5 
detrimental lipoprotein profile to atherosclerosis in men and women of the same age. This may be an 6 
explanation for the observation that women develop atherosclerosis and CVD later than men.
39
 It has 7 
been shown that while cholesterol is a slightly stronger risk factor in men, diabetes is a stronger 8 
cardiovascular risk factor in women than in men.
40
 Therefore, women of the same age may need an 9 
accumulation of multiple risk factors that are detrimental to the vascular endothelium to develop 10 
atherosclerosis. This may be due to vasoprotective effects of endogenous oestrogens,
41
 which is 11 
consistent with the marginally negative effects that we observed in premenopausal women, and no 12 
relation in postmenopausal women. Consequently, the underlying mechanisms of differing relations 13 
between CETP and cIMT may reach further than changes in lipid metabolism that are associated with 14 
endogenous oestrogens.  15 
Strengths of this study are the large study population with measurements of CETP, cIMT and 16 
genetic information to perform a Mendelian randomisation study in the general population. Moreover, 17 
extensive phenotypic data was available. Therefore, we were able to perform several subgroup 18 
analyses based on sex, menopausal status, medication use and cardiovascular risk factors. The present 19 
study also has some limitations that need to be considered. First, the use of cIMT as a measure of 20 
subclinical atherosclerosis may limit interpretation of the results in terms of cardiovascular risk. 21 
However, previous research has indicated that cIMT is strongly associated with the incidence of 22 
future cardiovascular disease in the general population.
42
  Second, performing several subgroup 23 
analyses increases the risk of chance findings. Further research is needed to replicate the observed 24 
relations. Third, this study was performed in a white middle-aged population. Genetic variants or the 25 
effects of CETP on atherosclerosis may be specific for this kind of population, and the results 26 
therefore need to be confirmed in other ethnicities. 27 
18 
 
The causal role of CETP is subject to controversy and at the moment of conceptualizing this 1 
study, three of four experimental studies of CETP inhibition had been halted due to a lack of 2 
protective effect. 
43-45
 If additional research confirms the potential subgroup effects of CETP, this may 3 
indicate that personalisation of pharmacotherapy may be a sensible strategy in the primary and 4 
secondary prevention of (recurrent) cardiovascular disease. Further research may elucidate the 5 
efficacy of intervening on CETP in subgroups of clinical trials that have been performed. We 6 
conclude that despite the absence of a relation between CETP and atherosclerosis in a population of 7 
men and women, this relation may be present in men with normal glucose, HDL-c and triglyceride 8 
concentrations, and women with a high cardiovascular risk profile or impaired fasting glucose. 9 
Further research may give insight in potential sex differences in the aetiology of atherosclerosis. 10 
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Within the NEO study, cIMT was determined in all participants. Precision of cIMT measurements 2 
is crucial to prevent misclassification, decreased study power and diluted effect estimates. We 3 
examined the reproducibility of the cIMT measurements in the common carotid artery. We performed 4 
paired scans of the cIMT in a random sample of participants at the baseline of the study. Of 169 5 
participants with repeated measurements, 76 participants were scanned twice by the same 6 
sonographerm, and 93 participants were scanned twice by two different sonographers. Sonographers 7 
were blinded for the scan of the other sonographer. All sonographers were right-handed research 8 
nurses who recently had been trained to measure cIMT by an experienced sonographer according to 9 
standardized procedures. 10 
To study agreement within and between sonographers we constructed Bland-Altman plots and 11 
calculated 95% limits of agreement (LA), intraclass correlation coefficients (ICCs)  and coefficients 12 
of variation (CVs) for intra-observer and inter-observer measurements separately. For the Bland-13 
Altman plots we calculated the mean cIMT of 2 paired measurements and the difference between 2 14 
paired cIMT measurements by subtracting the second measurement from the first measurement. The 15 
ICC explains how much of the total variance between measurements is caused by true inter-subject 16 
variability. An ICC of one represents perfect agreement and ICC of zero implies no agreement at all. 17 
The CV expresses the standard error between paired measurements as a percentage of the sample 18 
mean, where a CV of 0% equals perfect agreement and a CV of 100% signifies no agreement at all. 19 
We calculated the ICC and CV for the intra-observer measurements, as well as for the inter-observer 20 
measurements. 21 
The mean difference for the intra-observer measurement was -0.009 mm (SD 0.054, 95% LA -22 
0.114 mm to 0.097 mm,  Supplementary figure 1, Panel A) and the mean absolute difference was 23 
0.043 mm (SD 0.033). Sixty-nine (91%) intra-observer measurements had an absolute cIMT 24 
difference between paired measurements of less than 0.100 mm. The intra-observer ICC was 0.74 25 
(95% CI 0.62 to 0.83) and the CV was 5.8%. The inter-observer measurements had a mean difference 26 
of 0.000 mm (SD 0.084, 95% LA -0.164 mm to 0.164 mm, Supplementary figure 1, Panel B) and the 27 
26 
 
mean absolute difference was 0.064 mm (SD 0.054). Seventy-seven (83%) inter-observer 1 
measurements had an absolute cIMT difference between paired measurements of less than 0.100 mm. 2 





Supplementary figure 1 – Bland-Altman plots representing the difference between repeated cIMT measurements by the 2 
absolute mean cIMT of the repeated measurement. Solid lines represent 95% limits of agreement (LA).  Panel A presents the 3 
intra-observer variation, panel B presents the inter-observer variation. 4 




Supplementary figure 2 – Plots representing the absolute difference in repeated cIMT measurements by the mean of 2 
the repeated measurements. Grey solid lines represent the 95% confidence intervals of the regression line. Panel A represents 3 
the intra-observer variation, panel B represents the inter-observer variation. 4 
